ABSTRACT
OBJECTIVE: Subtle decline in memory is thought to arise in the preclinical phase of Alzheimer's disease (AD). However, detecting these initial cognitive difficulties cross-sectionally has been challenging, and the exact nature of the decline is still debated. Accelerated long-term forgetting (ALF) has been recently suggested as one of the earliest and most sensitive indicators of memory dysfunction in subjects at risk of developing AD. The objective of this study was to design and validate the 1-week memory battery (1WMB) for assessing episodic memory and ALF in cognitively unimpaired individuals. METHOD: The 1WMB is unique in that it assesses multimodal memory and measures recall at both short delay (20 min) and at long term (1 week). Forty-five cognitively unimpaired subjects were assessed with 1WMB and standardized neuropsychological tests. Subjective cognitive decline (SCD), levels of anxiety and depression, and cognitive reserve were also measured. RESULTS: The tests of 1WMB showed a high internal consistency, and concurrent validity was observed with standard tests of episodic memory and executive functions. The analysis revealed a greater loss of information at 1 week compared to short-term forgetting (20 min). Performance in the 1WMB was affected by age and educational level, but was not associated with levels of anxiety and depression. Unlike standard tests, performance in the 1WMB correlated with measures of SCD. CONCLUSION: Our findings indicate that the 1WMB has good psychometric properties, and future studies are needed to explore its potential usefulness to assess cognitively unimpaired subjects at increased risk of developing AD. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Memory, Episodic , Humans , Neuropsychological Tests , Alzheimer Disease/psychology , Mental Recall , Executive Function , Memory Disorders/diagnosis , Memory Disorders/etiology , Memory Disorders/psychologyABSTRACT
OBJECTIVES: Early- and late-onset Alzheimer's disease (EOAD and LOAD) share the same neuropathological traits but show distinct cognitive features. We aimed to explore baseline and longitudinal outcomes of global and domain-specific cognitive function in a well characterized cohort of patients with a biomarker-based diagnosis. METHODS: In this retrospective cohort study, 195 participants were included and classified according to their age, clinical status, and CSF AD biomarker profile: 89 EOAD, 37 LOAD, 46 young healthy controls (age ≤ 65 years), and 23 old healthy controls (>65 years). All subjects underwent clinical and neuropsychological assessment, neuroimaging, APOE genotyping and lumbar puncture. RESULTS: We found distinct neuropsychological profiles between EOAD and LOAD at the time of diagnosis. Both groups showed similar performances on memory and language domains, but the EOAD patients displayed worsened deficits in visual perception, praxis, and executive tasks (p < 0.05). Longitudinally, cognitive decline in EOAD was more pronounced than LOAD in the global outcomes at the expense of these non-amnestic domains. We found that years of education significantly influenced the decline in most of the neuropsychological tests. Besides, the APOE ε4 status showed a significant effect on the decline of memory-related tasks within the EOAD cohort (p < 0.05). INTERPRETATION: Age of onset is a main factor shaping the cognitive trajectories in AD patients, with younger age driving to a steeper decline of the non-memory domains. Years of education are related to a transversal decline in all cognitive domains and APOE ε4 status to a specific decline in memory performance in EOAD.
Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Humans , Aged , Alzheimer Disease/pathology , Retrospective Studies , Age of Onset , Cognitive Dysfunction/etiology , Neuropsychological TestsABSTRACT
BACKGROUND: MRI atrophy predicts cognitive status in AD. However, this relationship has not been investigated in early-onset AD (EOAD, < 65 years) patients with a biomarker-based diagnosis. METHODS: Forty eight EOAD (MMSE ≥ 15; A + T + N +) and forty two age-matched healthy controls (HC; A - T - N -) from a prospective cohort underwent full neuropsychological assessment, 3T-MRI scan and lumbar puncture at baseline. Participants repeated the cognitive assessment annually. We used linear mixed models to investigate whether baseline cortical thickness (CTh) or subcortical volume predicts two-year cognitive outcomes in the EOAD group. RESULTS: In EOAD, hemispheric CTh and ventricular volume at baseline were associated with global cognition, language and attentional/executive functioning 2 years later (p < 0.0028). Regional CTh was related to most cognitive outcomes (p < 0.0028), except verbal/visual memory subtests. Amygdalar volume was associated with letter fluency test (p < 0.0028). Hippocampal volume did not show significant associations. CONCLUSION: Baseline hemispheric/regional CTh, ventricular and amygdalar volume, but not the hippocampus, predict two-year cognitive outcomes in EOAD.
Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Alzheimer Disease/complications , Alzheimer Disease/diagnostic imaging , Alzheimer Disease/pathology , Atrophy/pathology , Cognition , Cognitive Dysfunction/diagnostic imaging , Cognitive Dysfunction/etiology , Cognitive Dysfunction/pathology , Hippocampus/pathology , Humans , Language , Magnetic Resonance Imaging , Neuropsychological Tests , Prospective StudiesABSTRACT
There is evidence of longitudinal atrophy in posterior brain areas in early-onset Alzheimer's disease (EOAD; aged < 65 years), but no studies have been conducted in an EOAD cohort with fluid biomarkers characterization. We used 3T-MRI and Freesurfer 6.0 to investigate cortical and subcortical gray matter loss at two years in 12 EOAD patients (A + T + N + ) compared to 19 controls (A-T-N-) from the Hospital Clínic Barcelona cohort. We explored group differences in atrophy patterns and we correlated atrophy and baseline CSF-biomarkers levels in EOAD. We replicated the correlation analyses in 14 EOAD (A + T + N + ) and 55 late-onset AD (LOAD; aged ≥ 75 years; A + T + N + ) participants from the Alzheimer's disease Neuroimaging Initiative. We found that EOAD longitudinal atrophy spread with a posterior-to-anterior gradient and beyond hippocampus/amygdala. In EOAD, higher initial CSF NfL levels correlated with higher ventricular volumes at baseline. On the other hand, higher initial CSF Aß42 levels (within pathological range) predicted higher rates of cortical loss in EOAD. In EOAD and LOAD subjects, higher CSF t-tau values at baseline predicted higher rates of subcortical atrophy. CSF p-tau did not show any significant correlation. In conclusion, posterior cortices, hippocampus and amygdala capture EOAD atrophy from early stages. CSF Aß42 might predict cortical thinning and t-tau/NfL subcortical atrophy.
Subject(s)
Alzheimer Disease , Alzheimer Disease/diagnostic imaging , Alzheimer Disease/pathology , Amyloid beta-Peptides , Atrophy/pathology , Biomarkers , Brain/diagnostic imaging , Brain/pathology , Humans , Magnetic Resonance Imaging , tau ProteinsABSTRACT
OBJECTIVES: We studied a sample of cognitively unimpaired individuals, with and without subjective cognitive decline (SCD), in order to investigate accelerated long-term forgetting (ALF) and to explore the relationships between objective and subjective cognitive performance and cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers. METHODS: Fifty-two individuals were included and SCD was quantified through the Subjective Cognitive Decline Questionnaire (SCD-Q), using its validated cutoff to classify participants as Low SCD-Q (n = 21) or High SCD-Q (n = 31). These groups were further subdivided according to the presence or absence of abnormal levels of CSF Aß42 . Objective cognitive performance was assessed with the Ancient Farming Equipment Test (AFE-T), a new highly-demanding test that calls for acquisition and retention of novel object/name pairs and allows measuring ALF over a 6-month period. RESULTS: The High SCD-Q group showed a significantly higher free forgetting rate at 3 months compared to the Low SCD-Q (F [1,44] = 4.72; p < 0.05). When stratifying by amyloid status, High SCD-Q/Aß+ showed a significantly lower performance than High SCD-Q/Aß-on the final free and cued learning scores (F [1,27] = 6.44, p < 0.05 and F [1,27] = 7.51, p < 0.05, respectively), the 1-week free and cued recall (F [1,24] = 4.49; p < 0.05 and F [1,24] = 7.10; p < 0.01, respectively), the 1-week cued forgetting rate (F [1,24] = 5.13; p < 0.05), and the 3-month cued recall (F [1,24] = 4.27; p < 0.05). Linear regression analyses showed that higher SCD-Q scores were associated with higher forgetting rates on the AFE-T (ß = -0.212; p < 0.05). CONCLUSIONS: It is possible to detect ALF in individuals with high SCD ratings, appearing especially in those with abnormal CSF Aß42 levels. Both in research and the clinical field, there is an increasing need of using more demanding cognitive measures, such as the AFE-T, for identifying and tracking the earliest cognitive changes in these populations.
Subject(s)
Alzheimer Disease , Cognitive Dysfunction , Amyloid beta-Peptides , Biomarkers , Humans , Neuropsychological TestsABSTRACT
OBJECTIVE: Progranulin-related frontotemporal dementia (FTD-GRN) is a fast progressive disease. Modelling the cascade of multimodal biomarker changes aids in understanding the aetiology of this disease and enables monitoring of individual mutation carriers. In this cross-sectional study, we estimated the temporal cascade of biomarker changes for FTD-GRN, in a data-driven way. METHODS: We included 56 presymptomatic and 35 symptomatic GRN mutation carriers, and 35 healthy non-carriers. Selected biomarkers were neurofilament light chain (NfL), grey matter volume, white matter microstructure and cognitive domains. We used discriminative event-based modelling to infer the cascade of biomarker changes in FTD-GRN and estimated individual disease severity through cross-validation. We derived the biomarker cascades in non-fluent variant primary progressive aphasia (nfvPPA) and behavioural variant FTD (bvFTD) to understand the differences between these phenotypes. RESULTS: Language functioning and NfL were the earliest abnormal biomarkers in FTD-GRN. White matter tracts were affected before grey matter volume, and the left hemisphere degenerated before the right. Based on individual disease severities, presymptomatic carriers could be delineated from symptomatic carriers with a sensitivity of 100% and specificity of 96.1%. The estimated disease severity strongly correlated with functional severity in nfvPPA, but not in bvFTD. In addition, the biomarker cascade in bvFTD showed more uncertainty than nfvPPA. CONCLUSION: Degeneration of axons and language deficits are indicated to be the earliest biomarkers in FTD-GRN, with bvFTD being more heterogeneous in disease progression than nfvPPA. Our data-driven model could help identify presymptomatic GRN mutation carriers at risk of conversion to the clinical stage.
Subject(s)
Cognition/physiology , Frontotemporal Dementia/genetics , Gray Matter/diagnostic imaging , Mutation , Progranulins/genetics , White Matter/diagnostic imaging , Aged , Biomarkers , Brain/diagnostic imaging , Disease Progression , Female , Frontotemporal Dementia/blood , Frontotemporal Dementia/diagnostic imaging , Humans , Language , Magnetic Resonance Imaging , Male , Middle Aged , Neurofilament Proteins/blood , Neuropsychological Tests , PhenotypeABSTRACT
Accelerated long-term forgetting (ALF) refers to a rapid loss of information over days or weeks despite normal acquisition/encoding. Notwithstanding its potential relevance as a presymptomatic marker of cognitive dysfunction, no study has addressed the relationship between ALF and Alzheimer's disease (AD) biomarkers. We examined ALF in APOE É4 carriers versus noncarriers, and its relationships with AD cerebrospinal fluid (CSF) biomarkers. We found ALF over three months in APOE É4 carriers (F(1,19) = 5.60; P < 0.05; Cohen's d = 1.08), and this performance was associated with abnormal levels of the CSF Aß42 /ptau ratio (r = -.614; P < 0.01). Our findings indicate that ALF is detectable in at-risk individuals, and that there is a relationship between ALF and the pathophysiological processes underlying AD.
Subject(s)
Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/genetics , Apolipoproteins E/genetics , Biomarkers/cerebrospinal fluid , Cognitive Dysfunction/cerebrospinal fluid , Cognitive Dysfunction/genetics , Aged , Alzheimer Disease/physiopathology , Amyloid beta-Peptides/cerebrospinal fluid , Cognitive Dysfunction/physiopathology , Dementia/cerebrospinal fluid , Dementia/diagnosis , Dementia/genetics , Female , Heterozygote , Humans , Male , Middle Aged , Peptide Fragments , Time Factors , tau Proteins/cerebrospinal fluidABSTRACT
Early-onset Alzheimer's disease (EOAD) and frontotemporal dementia (FTD) have a high proportion of genetically determined cases. Next-generation sequencing technologies have triggered the discovery of new mutations and genetic variants in dementia-causal genes. We performed whole-exome sequencing and selective analysis of known genes causative of EOAD and FTD in a well-characterized Spanish cohort of 103 patients (60 EOAD, 43 FTD) to find genetic variants associated to patients' phenotype. In EOAD patients, a new likely pathogenic variant in PSEN1 gene (p.G378R) was found. In FTD patients, 2 likely pathogenic variants were found, one in MAPT gene (p.P397S) and one in VCP gene (p.R159H). In our series, 2% of early-onset dementia without criteria for clinical genetic testing according to current guidelines presented a likely pathogenic mutation. We have also detected 13 additional variants of uncertain significance in causal genes, as well as rare variants in risk genes for dementia (ABCA7, SORL1, SQSTM1, and TREM2). Next-generation technologies in neurodegenerative diseases constitute a powerful tool that significantly contributes to patients' diagnosis.
Subject(s)
Alzheimer Disease/genetics , Genetic Association Studies/methods , Genetic Variation , Mutation , Presenilin-1/genetics , Valosin Containing Protein/genetics , ATP-Binding Cassette Transporters/genetics , Female , Humans , LDL-Receptor Related Proteins/genetics , Male , Membrane Glycoproteins/genetics , Membrane Transport Proteins/genetics , Middle Aged , Receptors, Immunologic/genetics , Retrospective Studies , Risk , Risk Factors , Sequestosome-1 Protein/genetics , Spain , Exome SequencingABSTRACT
Prior studies have described distinct patterns of brain gray matter and white matter alterations in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD), as well as differences in their cerebrospinal fluid (CSF) biomarkers profiles. We aim to investigate the relationship between early-onset AD (EOAD) and FTLD structural alterations and CSF biomarker levels. We included 138 subjects (64 EOAD, 26 FTLD, and 48 controls), all of them with a 3T MRI brain scan and CSF biomarkers available (the 42 amino acid-long form of the amyloid-beta protein [Aß42], total-tau protein [T-tau], neurofilament light chain [NfL], neurogranin [Ng], and 14-3-3 levels). We used FreeSurfer and FSL to obtain cortical thickness (CTh) and fraction anisotropy (FA) maps. We studied group differences in CTh and FA and described the "AD signature" and "FTLD signature." We tested multiple regression models to find which CSF-biomarkers better explained each disease neuroimaging signature. CTh and FA maps corresponding to the AD and FTLD signatures were in accordance with previous literature. Multiple regression analyses showed that the biomarkers that better explained CTh values within the AD signature were Aß and 14-3-3; whereas NfL and 14-3-3 levels explained CTh values within the FTLD signature. Similarly, NfL levels explained FA values in the FTLD signature. Ng levels were not predictive in any of the models. Biochemical markers contribute differently to structural (CTh and FA) changes typical of AD and FTLD.
Subject(s)
14-3-3 Proteins/cerebrospinal fluid , Alzheimer Disease , Amyloid beta-Peptides/cerebrospinal fluid , Cerebral Cortex/pathology , Frontotemporal Dementia , Neurofilament Proteins/cerebrospinal fluid , Neurogranin/cerebrospinal fluid , Peptide Fragments/cerebrospinal fluid , tau Proteins/cerebrospinal fluid , Age of Onset , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/diagnostic imaging , Alzheimer Disease/pathology , Biomarkers/cerebrospinal fluid , Cerebral Cortex/diagnostic imaging , Diffusion Tensor Imaging , Female , Frontotemporal Dementia/cerebrospinal fluid , Frontotemporal Dementia/diagnostic imaging , Frontotemporal Dementia/pathology , Hippocampus/diagnostic imaging , Hippocampus/pathology , Humans , Magnetic Resonance Imaging , Male , Middle Aged , NeuroimagingABSTRACT
BACKGROUND: The diagnosis of incipient symptomatic stages of early-onset dementia is challenging. The magnetic resonance imaging (MRI) is an easy-access biomarker. OBJECTIVE: We aim to determine the distribution and diagnostic performance of the existing atrophy visual rating scales on MRI in initial stages of the most frequent neurodegenerative early onset dementias. METHODS: We evaluated the visual atrophy scales usefulness in two hundred subjects: seventy sporadic early onset Alzheimer's disease (AD) patients (48 amnestic and 22 non-amnestic), 14 patients with autosomal-dominant AD (ADAD), 25 sporadic frontotemporal dementia patients [11 with behavioral variant (bvFTD), nine with semantic variant of primary progressive aphasia (svPPA), and 5 with non-fluent primary progressive aphasia (nfvPPA)], 7 with genetically determined FTD (genetic FTD), 25 mild cognitive impairment due to non-degenerative disorders, and 59 healthy controls. All had MMSE≥18, 3T-brain MRI, and biomarker-supported diagnosis. Two raters evaluated six frontal, temporal, and parietal scales. Inter-rater reliability and diagnostic performance in terms of area under the receiver-operator curves and balanced accuracy were analyzed. RESULTS: Best scales to discriminate AD from controls were the anterior cingulate scale for amnestic and the posterior atrophy scale for sporadic non-amnestic AD and ADAD. The anterior temporal scale was the best for sporadic bvFTD and svPPA and the anterior cingulate scale was for nfvPPA. All scales performed well for the genetic FTD. However, no scale demonstrated good performance at discriminating AD from FTD or non-degenerative disorders. CONCLUSIONS: The clinicians should interpret with caution atrophy scale assessment in subjects with early-onset cognitive impairment given that none of the evaluated scales met the requirements for being a diagnostic biomarker.
Subject(s)
Cognitive Dysfunction/diagnostic imaging , Cognitive Dysfunction/diagnosis , Magnetic Resonance Imaging/methods , Alzheimer Disease/diagnosis , Alzheimer Disease/diagnostic imaging , Aphasia, Primary Progressive/diagnosis , Aphasia, Primary Progressive/diagnostic imaging , Atrophy , Biomarkers/cerebrospinal fluid , Diagnosis, Differential , Female , Frontotemporal Dementia/diagnosis , Frontotemporal Dementia/diagnostic imaging , Gyrus Cinguli/diagnostic imaging , Humans , Image Interpretation, Computer-Assisted/methods , Male , Mental Status and Dementia Tests , Middle Aged , Observer Variation , Predictive Value of Tests , ROC Curve , Reproducibility of ResultsABSTRACT
BACKGROUND: Exploring the relationship between Alzheimer's disease (AD) biomarkers and subjective cognitive decline (SCD) is needed for better defining its clinical meaning in preclinical AD (preAD). OBJECTIVE: To assess the association between the Subjective Cognitive Decline Questionnaire (SCD-Q), gray matter (GM), and cerebrospinal fluid amyloid-ß (Aß). METHODS: 56 cognitively healthy older adults and their informants answered the SCD-Q. Correlations between GM and SCD-Q scores were explored using structural voxel-based morphometry models including Aß levels. SCD-Q*Aß vectors were calculated with higher scores reflecting higher SCD and cerebral amyloid, simultaneously. Subjects were classified according to their perception of cognitive worsening in the last two years, exploring for GM differences between-groups. RESULTS: Higher self-reported SCD-Q scores correlated with reduced GM in the right frontal lobe and increased volumes in the occipital lobe, calcarine sulcus, fusiform gyrus, and cerebellum, while higher informant's scores correlated with increased GM in the right middle temporal gyrus. Correlations were more significant for SCD-Q language items, self-complaints, and more positive than negative correlations were found. The SCD-Q*Aß vectors were negatively associated with GM both in self and informant's reports. Finally, lower Aß levels related to lower GM in subjects who noticed cognitive worsening, but related to higher GM in subjects who have not noticed this decline. CONCLUSIONS: Our results suggest that SCD-Q scores relate with incipient brain changes that may be due to preAD. Independent studies are needed to confirm our observations.
Subject(s)
Amyloid beta-Peptides/cerebrospinal fluid , Cognitive Dysfunction/diagnosis , Gray Matter/diagnostic imaging , Aged , Aged, 80 and over , Apolipoproteins E/genetics , Biomarkers/cerebrospinal fluid , Cognitive Dysfunction/diagnostic imaging , Cognitive Dysfunction/psychology , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Organ Size/physiology , Phosphorylation , Surveys and Questionnaires , tau Proteins/cerebrospinal fluidABSTRACT
Since the current neuropsychological assessments are not sensitive to subtle deficits that may be present in cognitively normal subjects with amyloid-ß positivity, more accurate and efficient measures are needed. Our aim was to investigate the presence of subtle motor deficits in this population and its relationship with cerebrospinal fluid (CSF) amyloid-ß levels. We adapted the Finger Tapping Task to measure tapping speed and intrasubject variability. Seventy-two right-handed participants completed the study. Subjects were divided into three groups according to their CSF biomarker profile: 37 control participants (negative CSF AD biomarkers, CTR), 20 cognitively normal subjects with amyloid-ß positivity (abnormal levels of CSF Aß42, Aß+) and 15 AD patients. All subjects underwent lumbar puncture for the CSF analysis, apolipoprotein E genotyping and completed the Finger Tapping Task, a neuropsychological battery and cardiovascular risk factor and physical activity assessments. An overall difference between groups was found both in tapping speed [F(2,66) = 19.37, p < .01] and in intrasubject variability [F(2,66) = 11.40, p < .01]. More specifically, the Aß+ group showed lower speed [F(1,52) = 5.33, p < .05] and greater intrasubject variability [F(1,52) = 8.48, p < .01] than the CTR group, and higher speed than the AD group [F(1,30) = 13.61, p < .01]. Speed (ß = .263, p < .05) and intrasubject variability (ß = -.558, p < .01) were significantly associated with CSF amyloid-ß levels. The present findings suggest that subtle motor difficulties can be detected in cognitively healthy subjects with amyloid-ß positivity and be related to CSF Aß42 levels. An accurate assessment of motor functions could help on identifying individuals at the earliest stage of the Alzheimer's continuum.
Subject(s)
Alzheimer Disease/metabolism , Amyloid beta-Peptides/metabolism , Early Diagnosis , tau Proteins/metabolism , Aged , Aged, 80 and over , Alzheimer Disease/diagnosis , Alzheimer Disease/psychology , Biomarkers/analysis , Cognition/physiology , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Positron-Emission Tomography/methodsABSTRACT
NIA-AA diagnostic criteria include volumetric or visual rating measures of hippocampal atrophy (HA) as a diagnostic biomarker of Alzheimer's disease (AD). We aimed to determine its utility as a diagnostic biomarker for early onset Alzheimer's disease (EOAD) by assessing Medial Temporal Atrophy (MTA) and hippocampal volume (HV) determination. MTA score and HV quantified by FreeSurfer were assessed in 140 (aged ≤65) subjects with biomarker supported diagnosis: 38 amnesic (A-EOAD), 20 non-amnesic (NA-EOAD), 30 late onset AD (LOAD), 20 fronto-temporal dementia (FTD) and 32 healthy controls (HC). The results showed that the proportion of MTAâ¯≥â¯1.5 was higher on LOAD and FTD than EOAD and HC but none of the MTA thresholds (≥1, ≥1.5 andâ¯≥â¯2) showed acceptable diagnostic accuracy. LOAD had lower HV than the other groups. A-EOAD HV was lower than NA-EOAD and HC but equal to FTD. The 6258â¯mm3 cut-off showed good diagnostic accuracy between A-EOAD and HC. Both tools showed a moderate inverse correlation. In conclusion, MTA has a limited diagnostic utility as an EOAD biomarker as it does not discriminate AD from FTD or HC in initial symptomatic stages. HV may discriminate A-EOAD from HC but not from FTD.
Subject(s)
Alzheimer Disease/diagnostic imaging , Amnesia/diagnostic imaging , Frontotemporal Dementia/diagnostic imaging , Hippocampus/diagnostic imaging , Magnetic Resonance Imaging/standards , Neuroimaging/standards , Age of Onset , Aged , Atrophy/diagnostic imaging , Biomarkers , Female , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Neuroimaging/methodsABSTRACT
Mutations in the MAPT gene cause frontotemporal dementia with tau deposits. We report the novel p.P397S MAPT variant in eight subjects from five apparently nonrelated families suffering from frontotemporal dementia with autosomal dominant pattern of inheritance. In silico analysis reported conflicting evidence of pathogenicity. The segregation analysis support that this variant is likely pathogenic. The mean age at onset (61.4 years) and mean disease duration (13.9 years) of these subjects and their affected relatives were significantly higher compared with our series of p.P301L MAPT mutation carriers. These findings suggest that p.P397S variant could be a new MAPT mutation associated with a less aggressive phenotype than other MAPT mutations.
Subject(s)
Frontotemporal Dementia/genetics , Frontotemporal Dementia/physiopathology , tau Proteins/genetics , Age of Onset , Aged , Brain/physiology , Female , Genotype , Humans , Male , Middle Aged , Mutation , WillsABSTRACT
BACKGROUND: We investigated a sample of cognitively healthy subjects with normal Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarker levels to identify the earliest variables related to longitudinal memory changes. OBJECTIVE: Employing a new highly demanding learning and memory test (the Ancient Farming Equipment Test; AFE-T), we aimed to investigate whether a biomarker related to neurodegeneration (i.e., CSF tau) was associated with longitudinal memory decline. METHODS: Thirty-two cognitively and biologically normal (CBN) subjects underwent MRI, neuropsychological assessment, and the AFE-T at baseline and 18 months later. To explore the relationship between cognitive performance and relevant factors, a linear model was set up. For a secondary analysis that further explore the effect of tau, the subjects were divided into CBN-Tau↓ (tauâ<â228.64âpg/ml; nâ=â16) and CBN-Tau↑ (tauâ>â228.64âpg/ml; nâ=â16). We also performed voxel-based morphometry (VBM) to identify regions of grey matter volume that would predict both baseline and longitudinal cognitive performance. RESULTS: Our main finding was an association between CSF tau and longitudinal memory decline measured with AFE-T (Bâ=â-0.17, pâ<â0.05; râ=â-0.414; pâ<â0.01), and further analyses showed different evolvement between subgroups, with an accelerated decline in individuals with higher tau (F(1,31)â=â8.37; pâ<â0.01). VBM results suggested that AFE-T performance is related to grey matter volume in a medial temporal, middle frontal, and posterior cerebellar network at baseline, and that there are strategic brain areas driving the longitudinal cognitive changes. CONCLUSIONS: The present findings provide evidence for structural and biological markers linked to cognitive aging by highlighting the role of tau, a marker of neurodegeneration, which can be related with the earliest memory changes in healthy subjects.
Subject(s)
Alzheimer Disease/cerebrospinal fluid , Cognition/physiology , Cognitive Dysfunction/cerebrospinal fluid , Memory Disorders/cerebrospinal fluid , tau Proteins/cerebrospinal fluid , Aged , Alzheimer Disease/diagnostic imaging , Biomarkers/cerebrospinal fluid , Brain/diagnostic imaging , Cognitive Dysfunction/diagnostic imaging , Female , Healthy Volunteers , Humans , Magnetic Resonance Imaging , Male , Memory Disorders/diagnostic imaging , Middle Aged , Neuropsychological Tests , PhosphorylationABSTRACT
Recent studies suggest that hippocampus has different cortical connectivity and functionality along its longitudinal axis. We sought to elucidate the possible different pattern of atrophy in longitudinal axis of hippocampus between Amyloid/Tau pathology and TDP-43-pathies. Seventy-three presenile subjects were included: Amyloid/Tau group (33 Alzheimer's disease with confirmed cerebrospinal fluid [CSF] biomarkers), probable TDP-43 group (7 semantic variant progressive primary aphasia, 5 GRN and 2 C9orf72 mutation carriers) and 26 healthy controls. We conducted a region-of-interest voxel-based morphometry analysis on the hippocampal longitudinal axis, by contrasting the groups, covarying with CSF biomarkers (Aß42, total tau, p-tau) and covarying with episodic memory scores. Amyloid/Tau pathology affected mainly posterior hippocampus while anterior left hippocampus was more atrophied in probable TDP-43-pathies. We also observed a significant correlation of posterior hippocampal atrophy with Alzheimer's disease CSF biomarkers and visual memory scores. Taken together, these data suggest that there is a potential differentiation along the hippocampal longitudinal axis based on the underlying pathology, which could be used as a potential biomarker to identify the underlying pathology in different neurodegenerative diseases.
Subject(s)
Alzheimer Disease/pathology , Aphasia, Primary Progressive/pathology , Hippocampus/pathology , TDP-43 Proteinopathies/pathology , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/diagnostic imaging , Aphasia, Primary Progressive/diagnostic imaging , Biomarkers/cerebrospinal fluid , DNA-Binding Proteins/metabolism , Female , Hippocampus/diagnostic imaging , Humans , Male , Memory, Episodic , Middle Aged , Neuropsychological Tests , Retrospective Studies , TDP-43 Proteinopathies/metabolism , tau Proteins/cerebrospinal fluid , tau Proteins/metabolismABSTRACT
BACKGROUND: There is a need to specify the profile of subjective cognitive decline in preclinical Alzheimer's disease (preAD). OBJECTIVES: To explore specific items of the Subjective Cognitive Decline Questionnaire (SCD-Q) that discriminate preAD from normal aging. METHODS: 68 cognitively normal older adults were classified as controls (nâ=â52) or preAD (nâ=â16) according to amyloid-ß (Aß) levels. An exploratory factor analysis and item analysis of the SCD-Q were performed. Informant reports of the SCD-Q were used to corroborate the findings of self-reports. One-year neuropsychological follow-up was available. RESULTS: Four SCD-Q factors were extracted: EM-factor (episodic memory), A-factor (attention), O-factor (organization), and L-factor (language). PreAD reported a significantly higher decline in L-factor (F(1)â=â6.49; pâ=â0.014) and A-factor (F(1)â=â4.04; pâ=â0.049) compared to controls, and showed a higher frequency of perceived decline in SCD-Q items related with language and executive tasks (Sig-items.) Significant discriminative powers for Aß-positivity were found for L-factor (AUCâ=â0.75; pâ=â0.003) and A-factor (AUCâ=â0.74; pâ=â0.004). Informants in the preAD group confirmed significantly higher scores in L-factor and Sig-items. A significant time×group interaction was found in the Semantic Fluency and Stroop tests, with the preAD group showing a decrease in performance at one-year. CONCLUSIONS: Our results suggest that SCD-Q items related with language and executive decline may help in prediction algorithms to detect preAD. Validation in an independent population is needed.
Subject(s)
Alzheimer Disease/diagnosis , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/psychology , Executive Function , Language , Aged , Aging , Alzheimer Disease/psychology , Amyloid beta-Peptides/blood , Factor Analysis, Statistical , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Self ReportABSTRACT
We employed a highly demanding experimental associative learning test (the AFE-T) to explore memory functioning in Preclinical Alzheimer's Disease stage 1 (PreAD-1) and stage 2 (PreAD-2). The task consisted in the learning of unknown object/name pairs and our comprehensive setup allowed the analysis of learning curves, immediate recall, long-term forgetting rates at one week, three months, and six months, and relearning curves. Forty-nine cognitively healthy subjects were included and classified according to the presence or absence of abnormal CSF biomarkers (Control, nâ=â31; PreAD-1, nâ=â14; PreAD-2, nâ=â4). Control and PreAD-1 performances on the experimental test were compared by controlling for age and education. These analyses showed clear learning difficulties in PreAD-1 subjects (Fâ=â6.98; pâ=â0.01). Between-group differences in long-term forgetting rates were less notable, reaching statistical significance only for the three-month cued forgetting rate (Fâ=â4.83; pâ=â0.03). Similarly, relearning sessions showed only statistical trends between the groups (Fâ=â3.22; pâ=â0.08). In the whole sample, significant correlations between CSF Aß42/tau ratio and the AFE-T were found, both in the total learning score (râ=â0.52; pâ<â0.001) and in the three-month cued forgetting rate (râ=â-0.38; pâ<â0.01). Descriptive subanalyses involving PreAD-2 suggested greater learning and recall difficulties in these subjects when compared with the PreAD-1 group. The present results suggest that explicit learning difficulties when binding information could be one of the earliest signs of the future emergence of episodic memory difficulties on the Alzheimer's disease continuum. Our findings indicate that the AFE-T is a sensitive test, capable of detecting subtle memory difficulties in PreAD-1.
Subject(s)
Alzheimer Disease/diagnosis , Alzheimer Disease/psychology , Learning Disabilities/diagnosis , Learning Disabilities/etiology , Aged , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/complications , Amyloid beta-Peptides/cerebrospinal fluid , Apolipoproteins E/genetics , Biomarkers/cerebrospinal fluid , Disease Progression , Early Diagnosis , Female , Humans , Learning , Learning Disabilities/cerebrospinal fluid , Longitudinal Studies , Male , Memory , Middle Aged , Multivariate Analysis , Neuropsychological Tests , Peptide Fragments/cerebrospinal fluid , Prodromal Symptoms , Severity of Illness Index , tau Proteins/cerebrospinal fluidABSTRACT
BACKGROUND: Individuals with preclinical Alzheimer's disease (Pre-AD) present nonimpaired cognition, as measured by standard neuropsychological tests. However, detecting subtle difficulties in cognitive functions may be necessary for an early diagnosis and intervention. OBJECTIVES: A new computer-based visuomotor coordination task (VMC) was developed to investigate the possible presence of early visuomotor difficulties in Pre-AD individuals. Associations between VMC task performance and AD biomarkers were studied. The influence of ApoE status on participants' performance was addressed, as well as the relationship between performance and subjective cognitive decline (SCD). METHODS: Sixty-six cognitively normal (CN) elders (19 Pre-AD and 47 control participants [CTR]) and 15 patients with AD performed the VMC task, which consisted in executing visually guided goal-directed movements that required the coordination of the visual and motor systems. All participants underwent ApoE analysis and lumbar puncture. CN participants also completed an extensive standard neuropsychological battery. RESULTS: Despite presenting normal cognition in standard tests, Pre-AD participants exhibited higher response times (RTs) to complete the VMC task than CTR (p < .01). Besides, patients with AD showed higher RTs than CTR (p < .001) and Pre-AD (p < .05), and more errors than CTR (p < .005). RTs in ApoE4 carriers were higher than that observed in ApoE4 noncarriers (p < .01). In CN individuals, RTs were related to amyloid ß-protein 42 (AB42) biomarker (p < .01) and informant-rated SCD (p < .01). CONCLUSIONS: The VMC task is able to discriminate Pre-AD from CTR individuals. Moreover, VMC results are associated with AB42 levels in CN individuals, suggesting that visuomotor dysfunction may be a sensitive marker of Pre-AD.
Subject(s)
Alzheimer Disease/complications , Cognition Disorders/etiology , Psychomotor Disorders/etiology , Aged , Alzheimer Disease/cerebrospinal fluid , Alzheimer Disease/genetics , Alzheimer Disease/psychology , Amyloid beta-Peptides/cerebrospinal fluid , Apolipoproteins E/genetics , Cognition Disorders/diagnosis , Diagnosis, Computer-Assisted , Female , Humans , Male , Mental Recall , Middle Aged , Neuropsychological Tests , Peptide Fragments/cerebrospinal fluid , Psychological Tests , Psychomotor Disorders/diagnosis , Reaction Time/physiology , Statistics as TopicABSTRACT
BACKGROUND: Determination of Alzheimer's disease (AD) by cerebrospinal fluid (CSF) biomarkers - 42-amino-acid amyloid-ß (Aß42), total tau and phosphorylated tau (p-tau) - has demonstrated high validity for detecting AD neuropathological changes. However, their prognostic utility to predict the onset of dementia in predementia subjects is still questioned. We aimed to study the prospective clinical evolution of a group of subjects with subjective cognitive decline (SCD) or mild cognitive impairment (MCI) and to determine the prognostic capacity of AD CSF biomarkers. METHODS: 149 subjects with MCI or SCD, not meeting dementia criteria, underwent a prospective clinical, neuropsychological and CSF biomarker study. Patients were initially classified as SCD or MCI following internationally accepted criteria. CSF sampling was obtained and analysed following consensus protocols. Neuropsychological and clinical evaluations were conducted at the follow-up. Statistical analysis considering the final clinical diagnosis, regression analysis to define risk factors and survival curves for progression were made. RESULTS: 72.4% of subjects (83% MCI and 27% SCD) with a pathological CSF ratio (Aß42/p-tau) met criteria for dementia during the 5-year follow-up versus 18.7% of subjects from the group with a normal ratio. The pathological CSF ratio was a powerful marker of risk for AD dementia (OR 27.1; 95% CI 10.3-71.2). Kaplan-Meier survival curves showed that only 15% of subjects with a pathological CSF ratio remained free of AD dementia at 5 years of follow-up. All subjects who reverted to normal cognition presented a normal CSF profile at baseline. CONCLUSION: An abnormal AD CSF biomarker profile in predementia subjects is a powerful predictor of cognitive and/or functional decline in the medium term.